Enrolling Overweight Obstructive Sleep Apnoea Drug: NNC0487-0111 Drug: Placebo (matched to NNC0487-0111) Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL) This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)
Our focus extends beyond medicineswe believe in empowering patients, healthcare professionals, and communities through health education and disease awareness
Future studies will further elucidate the currently unrecognized metabolic landscape of TLS
Fernandes AB, Patarro RS, Videira PA, Macedo MP (2011) Understanding postprandial glucose clearance by peripheral organs: the role of the hepatic parasympathetic system
10.3390/nu11051171 Nutrients
In hepatocellular carcinoma (HCC), LCACs are effectively loaded into the mitochondria of lymphocytes, resulting in the inhibition of invariant natural killer T (iNKT) cell expansion and the promotion of their senescence while simultaneously facilitating tumor evasion of immune surveillance [66]
